BioCentury | Oct 27, 2014
Company News

Nuo Therapeutics sales and marketing update

...Nuo Therapeutics (formerly Cytomedix Inc. ) re-launched its AutoloGel System in the U.S. under the Aurix System...
BioCentury | Jun 30, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

...senior convertible notes Raised: $26 million Shares outstanding prior: 121.7 million Investor: Deerfield Management Note: Cytomedix...
BioCentury | May 26, 2014
Clinical News

ALD-401: Phase II data

...primary endpoint of improving mean mRS scores from baseline to day 90 vs. sham control. Cytomedix...
...Durham, N.C. Cytomedix expects the closure to save about $4 million per year. Last September, Cytomedix...
...2013, Cytomedix had $3.8 million in cash and a 12-month operating loss of $18.1 million. Cytomedix Inc....
BioCentury | Apr 7, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

...Raised: $9 million Placement agent: BTIG Shares outstanding prior: 114.6 million Investor: Deerfield Management Note: Cytomedix...
BioCentury | Apr 7, 2014
Company News

Cytomedix management update

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md. Business: Dermatology Hired: Dean Tozer as EVP and chief commercial officer, formerly VP of corporate development at the regenerative medicine unit of Shire plc WIR Staff Dermatology...
BioCentury | Apr 7, 2014
Financial News

Cytomedix completes private placement of common stock and warrants

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md. Business: Dermatology Date completed: 3/31/14 Type: Private placement of common stock and warrants Raised: $2 million Shares: 3.8 million Price: $0.52 Shares after offering: 114.6 million Placement agent: BTIG Investor:...
BioCentury | Dec 16, 2013
Clinical News

AutoloGel System regulatory update

...said the Centers for Medicare & Medicaid Services (CMS) issued final rules covering reimbursement for Cytomedix's...
...treatment for the reimbursement code assigned to AutoloGel for use in the hospital outpatient setting. Cytomedix...
...determine the payment amount for AutoloGel System for claims submitted from physician offices. According to Cytomedix...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

...of JAK kinase (JAK) and SYK, into Phase III testing by 2014 or 2015. 9/17/13 Cytomedix Inc....
...focus exclusively on commercializing AutoloGel, which it markets in the U.S. for chronic wound care. Cytomedix...
...ischemic heart failure and ALD-301 has completed a Phase I/II trial for critical limb ischemia. Cytomedix...
BioCentury | Sep 23, 2013
Company News

Cytomedix dermatology news

...with ALD-401 and the underlying ALDH Bright Cell technology. RECOVER-Stroke has enrolled 39 patients and Cytomedix...
...ALD-401 comprises stems cells derived from bone marrow expressing high levels of aldehyde dehydrogenase . Cytomedix...
...technology transfer, a spinout or licensing. Depending on the company's efforts to pursue strategic alternatives, Cytomedix...
BioCentury | Aug 19, 2013
Financial News

Cytomedix financial update

...on Sept. 1. Additionally, Cytomedix granted MidCap a first priority security interest in royalty payments Cytomedix...
...is approved in the U.S., Canada, Australia and countries in Europe and the Middle East. Cytomedix...
...down the $4.5 million first tranche of the loan in February (see BioCentury, Feb. 25). Cytomedix Inc....
Items per page:
1 - 10 of 60
BioCentury | Oct 27, 2014
Company News

Nuo Therapeutics sales and marketing update

...Nuo Therapeutics (formerly Cytomedix Inc. ) re-launched its AutoloGel System in the U.S. under the Aurix System...
BioCentury | Jun 30, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

...senior convertible notes Raised: $26 million Shares outstanding prior: 121.7 million Investor: Deerfield Management Note: Cytomedix...
BioCentury | May 26, 2014
Clinical News

ALD-401: Phase II data

...primary endpoint of improving mean mRS scores from baseline to day 90 vs. sham control. Cytomedix...
...Durham, N.C. Cytomedix expects the closure to save about $4 million per year. Last September, Cytomedix...
...2013, Cytomedix had $3.8 million in cash and a 12-month operating loss of $18.1 million. Cytomedix Inc....
BioCentury | Apr 7, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

...Raised: $9 million Placement agent: BTIG Shares outstanding prior: 114.6 million Investor: Deerfield Management Note: Cytomedix...
BioCentury | Apr 7, 2014
Company News

Cytomedix management update

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md. Business: Dermatology Hired: Dean Tozer as EVP and chief commercial officer, formerly VP of corporate development at the regenerative medicine unit of Shire plc WIR Staff Dermatology...
BioCentury | Apr 7, 2014
Financial News

Cytomedix completes private placement of common stock and warrants

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md. Business: Dermatology Date completed: 3/31/14 Type: Private placement of common stock and warrants Raised: $2 million Shares: 3.8 million Price: $0.52 Shares after offering: 114.6 million Placement agent: BTIG Investor:...
BioCentury | Dec 16, 2013
Clinical News

AutoloGel System regulatory update

...said the Centers for Medicare & Medicaid Services (CMS) issued final rules covering reimbursement for Cytomedix's...
...treatment for the reimbursement code assigned to AutoloGel for use in the hospital outpatient setting. Cytomedix...
...determine the payment amount for AutoloGel System for claims submitted from physician offices. According to Cytomedix...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

...of JAK kinase (JAK) and SYK, into Phase III testing by 2014 or 2015. 9/17/13 Cytomedix Inc....
...focus exclusively on commercializing AutoloGel, which it markets in the U.S. for chronic wound care. Cytomedix...
...ischemic heart failure and ALD-301 has completed a Phase I/II trial for critical limb ischemia. Cytomedix...
BioCentury | Sep 23, 2013
Company News

Cytomedix dermatology news

...with ALD-401 and the underlying ALDH Bright Cell technology. RECOVER-Stroke has enrolled 39 patients and Cytomedix...
...ALD-401 comprises stems cells derived from bone marrow expressing high levels of aldehyde dehydrogenase . Cytomedix...
...technology transfer, a spinout or licensing. Depending on the company's efforts to pursue strategic alternatives, Cytomedix...
BioCentury | Aug 19, 2013
Financial News

Cytomedix financial update

...on Sept. 1. Additionally, Cytomedix granted MidCap a first priority security interest in royalty payments Cytomedix...
...is approved in the U.S., Canada, Australia and countries in Europe and the Middle East. Cytomedix...
...down the $4.5 million first tranche of the loan in February (see BioCentury, Feb. 25). Cytomedix Inc....
Items per page:
1 - 10 of 60